Clinical Trial Update: A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients [Phase 3]

View source ↗

Summary

The document reports the completion of a Phase 3 double-blind trial evaluating KRN321 for treating anemia in cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• KRN321

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Anemia | Phase 3 | Status: COMPLETED